Identification | Back Directory | [Name]
1-((2R,3S,4R,5R)-3,4-dihydroxy-5-(hydroxyMethyl)-3-Methyltetrahydrofuran-2-yl)pyriMidine-2,4(1H,3H)-dione | [CAS]
114262-49-6 | [Synonyms]
Sofosbuvir metabolites GS331007 Sofosbuvir Methylarabinosyl Impurity Hydroxyuridine/Sofosbuvir Impurity 12 1-β-D-Arabinofuranosyluracil-2-C-methyl 1-(2'-C-methyl-β-D-arabinofuranosyl)uracil 1-(2-C-Methyl-β-D-arabinofuranosyl)-2,4(1H,3H)-pyrimidinedione 2,4(1H,3H)-Pyrimidinedione, 1-(2-C-methyl-β-D-arabinofuranosyl)- 1-((2R,3S,4R,5R)-3,4-dihydroxy-5-(hydroxyMethyl)-3-Methyltetrahydrofuran-2-yl)pyriMidine-2,4(1H,3H)-dione | [Molecular Formula]
C10H14N2O6 | [MOL File]
114262-49-6.mol | [Molecular Weight]
258.23 |
Hazard Information | Back Directory | [Uses]
1-β-D-Arabinofuranosyluracil-2-C-methyl is an impurity of PSI-7977 (P839640), a prodrug that is metabolized to the active antiviral agent 2''-deoxy-2''-α-fluoro-β-C-methyluridine-5''-monophosphate and is currently being investigated in phase 3 clinical trials for the treatment of hepatitis C. Studies have profiled PSI-7977 as a nucleotide inhibitor of hepatitis C virus, exerting selective inhibitory effects towards HCV NS5B polymerase. |
|
Company Name: |
SPIRO PHARMA
|
Tel: |
|
Website: |
www.spiropharma.com.cn |
Company Name: |
BOC Sciences
|
Tel: |
16314854226 |
Website: |
www.bocsci.com |
|